Mediwound announces fda acceptance of biologics license application for nexobrid

Mediwound announces fda acceptance of biologics license application for nexobrid for the treatment of severe thermal burns.mediwound ltd - fda assigned a prescription drug user fee act target date of june 29, 2021 for nexobrid.mediwound - in addition, fda communicated that it is not currently planning to hold an advisory committee meeting to discuss application for nexobrid.
MDWD Ratings Summary
MDWD Quant Ranking